Ant Group’s AQ Tops China’s AI-Native Healthcare Apps, Launching New Features for Chronic Disease and Elderly Care
29.10.2025 07:28:00 CET | Business Wire | Press release
Ant Group’s AI healthcare service AQ is now among China’s top 7 AI-native apps and the only healthcare app on the list, based on monthly active users, according to the latest report from QuestMobile on AI applications in China. Within this group, AQ achieved the highest compound growth rate of 83.4%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028871468/en/

Ant Group’s AI healthcare platform AQ introduces new features, including family health record sharing, to support chronic disease management and elderly care.
Since its public beta as an Alipay mini-program in September 2024 and official launch as an independent app in China in June 2025, the AQ platform has served 140 million users as of September 2025. It provides more than 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized health guidance.
These developments come amid China’s ongoing demographic transformation. By around 2035, more than 400 million people, or over 30% of the population, are expected to be aged 60 or above, according to projections by China’s National Health Commission. The shift is expected to drive growing healthcare demand, with AI-powered solutions set to play a key role in addressing it.
Through AQ, users can access digital services from over 5,000 hospitals, online consultations with 200,000 doctors, and support from more than 300 AI Doctor Agents, co-developed with leading physicians and top hospital departments across China.
AQ has recently rolled out a range of new features focused on chronic disease management and elderly care, helping older adults better manage their daily health and move toward healthier lives with AI support:
- Smart Data Recognition: Users can simply take a photo of their blood pressure monitor or blood glucose meter to receive intelligent data analysis, follow-up questions, and abnormal data alerts to ensure timely medical attention.
- AI-Powered Blood Pressure Monitoring: In partnership with Yuwell, one of China’s leading home healthcare device providers, the two companies have jointly launched an AI-powered blood pressure monitor in China that automatically uploads data and generates weekly health reports—with users’ authorization—to support blood pressure management.
- Medication Reminders: A new reminder function helps users with chronic conditions take their medication on time, reducing the risk of missed doses.
- Family Health Sharing: AQ now enables real-time sharing of health records among family members, allowing children to access their parents’ medical histories and health check reports to better support their ongoing care.
Powered by Ant Group’s Healthcare Large Model, which builds on more than a decade of medical expertise, AQ features advanced medical reasoning and multimodal interaction capabilities. The model consistently ranks first in both HealthBench and MedBench evaluations.
Through continuous innovation, Ant Group remains committed to building a more trustworthy, efficient, and inclusive healthcare ecosystem in China, enhancing the effectiveness of limited medical resources and promoting medical inclusion for all.
About Ant Group
Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit www.antgroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028871468/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom